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Patients with familial isolated pituitary adenoma are predisposed to pituitary adenomas, which in a
subset of cases is due to germline inactivating mutations of the aryl hydrocarbon receptor–interacting
protein (AIP) gene. Using Cre/lox and Flp/Frt technology, a conditional mouse model was generated to
examine the loss of the mouse homolog, Aip, in pituitary somatotrophs. By 40 weeks of age, .80% of
somatotroph specific Aip knockout mice develop growth hormone (GH) secreting adenomas. The for-
mation of adenomas results in physiologic effects recapitulating the human syndrome of acromegaly,
including increased body size, elevated serum GH and insulin-like growth factor 1 levels, and glucose
intolerance. The pretumorigenic Aip-deficient somatotrophs secrete excess GH and exhibit pathologic
hyperplasia associated with cytosolic compartmentalization of the cyclin-dependent kinase (CDK)
inhibitor p27kip1 and perinuclear accentuation of CDK-4. Following tumor formation, the Aip-deficient
somatotrophs display reduced expression of somatostatin receptor subtype 5 with impaired response to
octreotide. The delayed tumor emergence, even with loss of both copies of Aip, implies that additional
somatic events are required for adenoma formation. These findings suggest that pituitary hyperplasia
precedes adenomatous transformation in somatotroph-specific Aip-deficient mice and reveal potential
mechanisms involved in the pretumorigenic state that ultimately contribute to transformation.
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Pituitary adenomas are common monoclonal neoplasms of the anterior pituitary gland,
constituting 15% of all intracranial tumors [1, 2]. A number of genetic syndromes such as
multiple endocrine neoplasia type 1, the Carney complex, and familial isolated pituitary
adenoma predispose individuals to develop pituitary adenomas. Mutations in the gene
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encoding the aryl hydrocarbon receptor (AhR)–interacting protein (AIP) have been associated
with a unique pituitary adenoma predisposition (PAP; Online Mendelian Inheritance in Man
#102200) [3]. Somatotropinomas and prolactinomas are the predominant tumor subtypes
found among PAP families, although other types have been reported as well. To date, more
than 100 different germline mutations or sequence variants in this gene have been identified
in families that are predisposed to developing pituitary tumors [4–6]. Altogether 70% of
germline mutations are nonsense, deletion, insertion, and/or frameshifts, predicting trun-
cation or absence of the resulting protein. Hence,AIP appears to be a classic tumor suppressor
gene with tumors in affected patients showing loss of heterozygosity, i.e., somatic loss of the
wild-type allele.
In humans, AIP gene is located on chromosome 11q13 and consists of seven exons (the first
of which is untranslated), spanning 11.4 kb of genomic sequence. It encodes a ubiquitously
expressed cytoplasmic protein of 330 amino acids with three typical tetratricopeptide repeat
domains at its C-terminus and an extendeda-helix [7]. The protein product forms interactions
with a variety of proteins, including AhR, heat shock protein 90, phosphodiesterase 2A, RET,
and survivin [8–12], but it remains unclear how the loss of AIP leads to the development of
tumors.
In mice, the Aip gene is located on chromosome 19 and has an exon-intron organization
similar to that of the human gene. Murine Aip demonstrates 95% identity and 98% similarity
to human AIP at the amino acid level. As with many tumor suppressor gene knockouts,
conventional homozygousAip knockoutmice (Aip2/2) die in utero between embryonic days 10
and 14 [13]. These mice display severe cardiovascular defects, including heart deformation;
double outlet right ventricle, ventricular-septal defects and pericardial edema [13]. A recent
report of heterozygous Aip mice created through a gene trapping strategy revealed that
Aip+/2 animals areprone to thedevelopment of growthhormone (GH) secreting adenomas [14].
However, the embryonic lethality of homozygous Aip knockout mice has precluded the ability
to precisely study the pretumorigenic process and its effects following loss of both Aip
alleles—an event that appears to be required to instigate a cascade of tumorigenesis.
To overcome the early lethality of the germline homozygous null state and to study the
function of AIP during tumorigenesis, we engineered specific deletion of exons 5 to 7 of theAip
gene in somatotrophs using a Cre/loxP system. Mice in which exons 5 to 7 of Aipwere flanked
by loxP sites were generated. Exons 5 to 7 were then deleted from somatotrophs by breeding
the mice with mice expressing cre recombinase under the control of the rat GH promoter
(rGHp-Cre) [15]. Mice with conditional Aip deletions develop GH excess, which precedes the
development of somatotroph pituitary tumors. Findings in this model support the role of the
Aip gene as an important pituitary tumor suppressor, and specify the cellular and patho-
logical processes associated with the transition to neoplasia.
1. Materials and Methods
A. Animal Handling
All animal care protocols were approved by the Institutional Animal Care and Use com-
mittees (Northwestern University Feinberg School of Medicine, Chicago, IL, and Yonsei
University College of Medicine, Seoul, South Korea). Mice were housed under standard
conditions of light (12-hour light, 12-hour dark cycle; lights on at 7:00 AM) and temperature (22
to 24°C), with free access to standard rodent chow and water. All mice were maintained in
accordance with American Association of Laboratory Animal Care guidelines.
B. Generation of Aiploxp/loxp Mice
The mouse Aip locus was targeted through homologous recombination in embryonic stem cells
using the C57BL/6 mouse strain. Details of the strategy used to 464 construct the Aiplox/lox mice
are provided in Supplemental Materials and Methods and illustrated in Supplemental Fig. 1.
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C. Generation of rGHp-Cre tg/+; Aiplox/lox Mice
rGHp-Cre tg/+; Aiplox/+ mice were obtained by crossing rGHp-Cre tg/+ female mice, de-
veloped by Luque et al. [15], with male Aiplox/loxmice. Interbreeding of rGHp-Cre tg/+;Aiplox/+
mice produced homozygous disruption of theAip gene in somatotrophs rGHp-Cre tg/+;Aiplox/lox.
Methods for genotyping of mice are provided in Supplemental Materials and Methods.
D. Phenotypic and Hormone Analysis
Histomorphometric analyses, including body weight and crown–rump measurements, were
taken at the time of euthanization. Pituitary glands were imaged with magnetic resonance
imaging (MRI), using two mice per genotype at ages 18 and 80 weeks. Blood for GH and
prolactin assays was collected at between 8 and 10 AM after an overnight (12-hour) fast.
Additional details regarding the phenotypic, hormonal, and metabolic analyses are available
in Supplemental Materials and Methods. In enzyme-linked immunosorbent assay (ELISA)
for GH levels, the limit of detection, interassay coefficient of variation, and intra-assay co-
efficient of variation of GHmeasurements were 0.14to ~100.00 ng/mL, 3.2 to ~9.4%, and 2.9%
to 4.8%. During serial ELISA for GH levels, at least four samples that had been analyzed in
previous experiment were used to validate the in-house assay. ELISAs with less than 10%
differences of their values were designated appropriate.
E. Histologic Analysis
Pituitaries were fixed in 10% neutral buffered formalin, embedded in paraffin, and sectioned
at 5 mm. Paraffin-embedded sections were stained with hematoxylin and eosin or silver stain
for reticulin matrix. Immunohistochemical staining was performed using the streptavidin–
biotin peroxidase method, or the Gordon–Sweet silver staining method, as described in
Supplemental Materials and Methods. Staining conditions and primary antibody concentra-
tions are available in Supplemental Materials and Methods.
F. Octreotide Acetate Suppression Test
Control (30 weeks), and hyperplastic (18 weeks) or adenomatous somatotroph-specific Aip
knockout (sAIPKO; 30 weeks) mice were used for octreotide acetate suppression test.
Octreotide acetate was diluted with 0.9% sterile saline to the final concentration using two
different doses, as previously described [16]. Octreotide acetate (30 mg/kg or 500 mg/kg) of was
injected subcutaneously after overnight fasting. Each group consisted of five mice. For blood
sampling, the animals were anesthetized by inhalation of isoflurane. Blood samples for GH
were collected by periorbital sampling prior to injection and 60 and 120minutes postinjection.
G. Real-Time Reverse Transcription Polymerase Chain Reaction (RT-PCR)
Extraction of total RNA and real-time RT-PCR was conducted as described previously [17].
The primers for amplication are described in Supplemental Table 1. The results for relative
expression in mice with pituitary gland of control (30 weeks), hyperplasia (18 weeks), and
tumor (30weeks) were normalized to GAPDHmessenger RNA (mRNA) levels in each sample.
Results are expressed as means 6 standard errors from five mice for each group.
H. Statistical Analysis
Statistical analysis was performed using Microsoft Excel software and SPSS software
package for Windows (Version 18.0; IBM Corp., Armonk, NY). Tumor incidence data were
evaluated with two-tailed Student’s t test. Differences were assessed by Mann–Whitney U
test when comparing three groups and Wilcoxon signed rank test when comparing within
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each group. Results are expressed as mean 6 standard errors of the mean. A P value , 0.05
was considered statistically significant.
2. Results
A. Conditional Disruption of Aip in Pituitary Somatotrophs Alters Adult GH Secretion,
Resulting in Enhanced Somatic Growth
The design of the Aip targeting vector was constructed with a goal of ascertaining the
pathogenetic relevance of C-terminal sequence alterations or truncations that have been
reported in humans (Supplemental Fig. 1). Thus, exons 5 through 7 of the Aip gene,
encompassing the tetratricopeptide repeat domain, were floxed to permit Cre-mediated
excision. The Aiplox/lox mice did not display any gross physical or behavioral abnormali-
ties. Interbreeding of Aiplox/lox mice with mice expressing Cre recombinase under control of
the rat GH promoter (rGHp-Cretg+) followed by additional intercrossing of progeny, led to the
generation of homozygous sAIPKO (rGHpCretg+;Aiplox/lox) mice. The rGHp-Cretg+ mice were
previously shown to express the Cre recombinase almost exclusively in somatotrophs, with
expression observed in less than 10% of lactotroph [15]. Mice with monoallelic somatotroph
inactivation of Aip were followed during the course of the creation and development of mice
with biallelic inactivation of Aip. Approximately 30 such mice were generated. None of these
animals developed visible pituitary tumors at necropsy. The rGHp-Cretg/+ mice used in this
study are on a C57BL/6 background. The rGHpCretg-;Aiplox/lox mice served as controls for all
subsequent experiments in this study.
Control and sAIPKO animals were evaluated for up to 80 weeks for physiologic charac-
teristics, hormone secretion patterns, and pituitary tumor development. At 6weeks of age, the
bodyweights and crown–rump lengths ofmale and female sAIPKOmice were similar to those
of control mice, but beginning at 12 weeks of age, the growth rates for these parameters began
to diverge, with a period of accelerated linear growth and weight gain observed between 12
and 18 weeks. Beyond 18 weeks, linear growth leveled off and rate of weight gain tapered for
both sAIPKO and control mice, though both parameters remained significantly different
throughout the remainder of their lifespan [Fig. 1 (a–c)]. Mean body weight of sAIPKO fe-
males ranged from 38.3% to 51.6% greater than controls and for sAIPKOmales, ranged from
13.9% to 23.0% greater than controls. The mean difference in body weight was significantly
greater for sAIPKO females [15.2 g at 80 weeks old, 95% confidence interval (CI), 9.5 to 19.8]
compared with males (9.1 g at 80 weeks old, 95% CI, 4.6 to 16.2), such that the sAIPKO
females achieved body weights similar to their male genotypic counterparts, whereas the
typical sex differential in weights was observed in controls (4.2 g at 80 weeks old, 95% CI, 0.8
to 8.6). Along with increased body size, sizes of visceral organs were also increased in sAIPKO
mice, showing significantly bigger hearts, livers, and kidneys than controls (3.46 0.6 g vs 2.26
0.4 g, 37.76 4.4mg vs 24.16 5.8mg, and 0.66 0.1 g vs 0.46 0.1 g at 80weeks old, respectively,
all P values , 0.05).
To determine the somatotroph hormonal response to the functional loss ofAip, we obtained
sera from sAIPKO and control mice for measurement of GH levels. Peripheral GH levels of
overnight-fasted control and sAIPKO mice were 37.5 6 5.2 ng/ml and 34.8 6 6.3 ng/ml at
6 weeks of age, respectively [Fig. 1(d)]. In accordance with the onset of accelerated somatic
growth and increase in body weight, mean GH hormone levels of sAIPKO mice were sig-
nificantly elevated as comparedwith controlmice by 18weeks. ThemeanGH levelswere 3.71-
fold and 1.96-fold elevated at 18 weeks in female and males, respectively. Elevated GH levels
persisted thereafter during the transition period to the development of adenomas. Both control
and sAIPKO mice demonstrated higher mean GH levels in female vs male mice, as previously
described in rodents [18], indicating a preservation of the sexually dimorphic GH response. GH
levels of sAIPKOmicewere 42.46 8.1, 43.86 7.8, and 51.56 5.7 ng/mL inmale and 54.16 9.4,
51.76 7.8, and 57.46 4.8 ng/mL in female at 18, 24, and 30 weeks, respectively. Furthermore,
elevated insulin-like growth factor1 (IGF-1) levelswere also found in sAIPKOmice.At 18weeks,
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Figure 1. Somatotroph-specific AIP knockout mice exhibit an accelerated growth phase
beginning in adulthood in conjunction with hypersecretion of GH. (a) Photograph illustrating
greater overall size of male and female sAIPKO mice as compared with control mice, all at 40
weeks of age. Scale bar represents 1 cm. (b) Body weights of sAIPKO mice are significantly
greater than control mice, beginning at age 18 weeks throughout the remainder of their
lifespan (for weeks beyond 18, *P , 0.01). (c) Crown-rump lengths of sAIPKO knockout mice
are significantly greater than control mice, beginning at age 18 weeks and continuing
throughout lifespan (for weeks beyond 18, *P , 0.01). Open circles, control females; darkened
circles, sAIPKO females; open triangles, control males; darkened triangles, sAIPKO males.
(d) Mean GH levels are 1.8- to 3.6-fold elevated in sAIPKO mice as compared with control
mice. Statistically significant increases in peripheral GH levels in sAIPKO mice are evident
at 18 weeks and beyond (**P , 0.05). (e) Mean IGF-1 levels are 2.9-fold elevated in sAIPKO
mice as compared with control mice at 18 weeks old. (*P , 0.01). Vertical bars indicate
standard deviation. Horizontal bars indicate mean levels. Open circles, control mice;
darkened circles, sAIPKO mice. Age and sex-matched number of mice with each genotype is
eight at age above 18 weeks old and four at age below 12 weeks old.
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IGF-1 of sAIPKO mice and control mice were 545.3 6 64.7 (males: 517.4 6 74.5 and females:
574.86 41.7) ng/ml and 188.06 10.2 ng/ml, respectively (P values, 0.01), and these increased
levels persisted at ages thereafter.As a group, prolactin levelswere similar in control vs sAIPKO
mice. Peripheral prolactin level of control and sAIPKOmice were 35.56 8.1 ng/ml and 32.96
7.8 ng/ml at 18 weeks and also similar at 80 weeks of age.
We assayed random glucose levels and performed insulin tolerance testing to examine the
metabolic consequences of GH hypersecretion associated with somatotroph Aip loss. Be-
ginning at 30 weeks of age, sAIPKO mice displayed hyperglycemia with significantly higher
blood glucose levels in both male and females [Supplemental Fig. 2(a)]. Insulin tolerance
testing demonstrated a diminished response to intraperitoneal insulin and greater area
under the curve in the sAIPKO mice [Supplemental Fig. 2(b)–(d)].
B.Conditional Disruption of Aip in Somatotrophs Triggers PituitaryEnlargement Followed by
the Emergence of Adenomas
To investigate the morphologic response to Aip disruption in pituitary somatotrophs, the
macroscopic appearance of pituitaries were observed and compared in control vs sAIPKO
mice usingMRI [Fig. 2(a) and 2(b)]. Beginning at 18 weeks of age, diffuse enlargement of the
pituitary glands of sAIPKO mice became evident on MRI, and low-intensity signaling
adenomas appeared in older sAIPKO mice. Control and sAIPKO pituitaries appeared
similar on a macroscopic level up until approximately 18 weeks of age, at which time
pituitaries from sAIPKO mice appeared diffusely enlarged [Fig. 3(a)]. Macroscopically
visible tumors were identified in the sAIPKO mice beginning at 24 weeks [Fig. 3(a)]. In
measurements excluding regions encompassing visible macroscopic tumors, the mean pituitary
volumes of sAIPKO mice and control mice were similar up until 12 weeks of age [Fig. 3(b)]. By
18 weeks of age, mean pituitary volumes of sAIPKOmice were significantly greater than those
from control littermates in both sexes. Macroscopic tumors emerged in approximately 20% of
male and female sAIPKOmice at 24weeks, andby30weeks, 80%of sAIPKOmicehaddeveloped
macroscopically visible tumors [Fig. 3(c)]. The predilection for a pituitary growth surge was
particularly evident among female sAIPKO mice, whose pituitaries were significantly larger
than their male counterparts at time points beyond 26 weeks.
C. sAIPKO Pituitaries Display Diffuse Pathologic Hyperplasia Prior to
Neoplastic Transformation
Microscopically, the pituitaries of neonatal and younger adult (18 weeks and under) control
mice appeared identical to sAIPKO pituitaries on routine hematoxylin and eosin staining of
adenohypophysial tissue. Hematoxylin and eosin pituitary sections from control mice showed
of a mixture of polygonal acidophils and basophils arranged within a normal architecture of
cords and nests [Fig. 4(a)]. The adenohypophyses of sAIPKO mice at 24 weeks of age
displayed a slight predominance of cells with acidophilic cytoplasm, but were otherwise
indistinguishable from control pituitary tissues on hematoxylin and eosin stained sections.
The adenohypophyses from older sAIPKO mice at 40 weeks and beyond demonstrated ir-
regularly shaped cells with atypical nuclei. No invasion of acinar tissue or extrapituitary
metastasis was observed in any of the sAIPKO mice.
To precisely ascertain whether the processes of pituitary hyperplasia and/or neoplasia
were evident, Gordon–Sweet silver staining of control and sAIPKO pituitary tissue was
performed [Fig. 4(a)]. Whereas the adenohypophysial tissue from control mice consisted of
small acini of pituitary cells surrounded by an intact reticulin network, adenohypophysial
tissue from sAIPKO mice between the ages of 12 and 24 weeks showed larger acini with
partial disruption of the reticulin fiber network. In sAIPKO mice older than 40 weeks of age,
silver staining revealed expanded acini and complete disruption of the reticulin pattern,
which are findings pathognomonic for adenomatous transformation. Detailed investigation into
the timing of these changes revealed that the hyperplastic response observed in sAIPKO
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Figure 2. Radiologic imaging showing pituitaries of somatotroph-specific AIP knockout mice
progressively enlarge during adulthood prior to adenomatous transformation. Control and
sAIPKO mice were studied at each time point. (a, b) MRI reveals change in radiographic
appearance of the sAIPKO mice: (a) Sagittal and (b) coronal images demonstrate pituitary
enlargement at 18 weeks, proceeding to findings on imaging consistent with adenoma at 80
weeks. Left two panels represent control mice pituitaries at 18 weeks and 80 weeks, middle
panels represent pituitary enlargement in sAIPKO mice at 18 weeks, and right two panels
represent pituitary adenomas in sAIPKO mice at 18 weeks and 80 weeks, respectively. (c)
Representative photomicrograph of histologic sections from sAIPKO mouse pituitary
adenomas demonstrating absent immunoreactivity for AIP (left), abundant immunoreactivity
for GH (middle), and absent immunoreactivity for prolactin (right) at 40 weeks. Pituitary
gland of age and sex matched control mouse was also demonstrated. Scale bar for each is
200 mm. White arrow indicates the pituitary gland and T means the area of pituitary tumor.
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pituitaries became pathologically evident at between 12 and 18weeks, as it was at the latter time
point that the mean number of pituitary cells per acina (28.346 7.24 vs 11.096 0.80) and mean
acinar area (2.01- 6 0.45-fold compared with control from sAIPKO pituitary glands) became
significantly larger than those of control litter mates [Fig. 4(b) and 4(c)]. The mean pituitary
acinar area fromsAIPKOmice continued to increase in sizeuntil stabilizingat itsmaximal size at
40 weeks [Fig. 4(c)]. Immunohistochemistry of adenomatous tissue showed a diffuse cytoplasmic
GH immunoreactivity, and absence of immunoreactivity for Aip and prolactin [Fig. 2(c)].
D. Loss of Somatotroph AIP Disrupts Cell-Cycle Regulator Expression and Localization
Given the pivotal role of G1 cyclin dependent kinases (CDKs) and CDK inhibitors (CDKIs) in
pituitary cell-cycle control and homeostasis, we hypothesized that altered expression of
Figure 3. Pituitary enlargement is followed sequentially by tumor development in
somatotroph-specific AIP knockout mice. (a) Gross pituitary appearance in control vs sAIPKO
knockout mice. A representative photograph of a control mouse pituitary at 40 weeks of age
is compared with a homogeneously enlarged pituitary from a sAIPKO mouse evident at 18
weeks of age, an adenomatous pituitary from a sAIPKO mouse found at 40 weeks of age, and
an invasive pituitary tumor from sAIPKO mouse at 80 weeks of age. Scale bar indicates
1 mm. (b) Pituitary volumes of sAIPKO and control mice are similar at 12 weeks. Beginning
at 18 weeks, male and female sAIPKO pituitaries show significantly greater volume as
compared with control littermates. Whereas pituitary size from control mice stabilizes after
12 weeks, the pituitaries from male sAIPKO mice exhibit further growth from 12 to 18
weeks, and pituitaries from female sAIPKO mice continue to grow through the lifespan.
(*P , 0.01). Open bars, male control; dotted, male sAIPKO; diagonal stripe, female control;
black, female sAIPKO. (c) Chart of pituitary adenoma incidence in control vs sAIPKO mice
shows that the tumors begin to appear at 24 weeks and beyond in both sexes, with a rapid
increase between 24 and 30 weeks of age. Control mice develop microscopic tumors at a low
overall prevalence (,20%) beyond 40 weeks of age. Open triangle, male control; open circle,
female control; black triangle, male sAIPKO; black circle, female sAIPKO. Open rectangles
represent mean of both sexes in controls and black rectangles represent mean of both sexes
in sAIPKO mice. The number of age and sex-matched mice for each genotype is at eight at
age above 18 weeks old and four at age below 12 weeks old.
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selected cell-cycle regulators might contribute to the deregulated cellular proliferation and
process of tumor development initiated by Aip gene inactivation. The current study focuses on
p27 andCDK4, as in vivo disruption of these two cell-cycle regulators display prominentmurine
pituitary phenotypes [19, 20]. Immunohistochemistry was performed on paraffin-embedded
Figure 4. Pituitaries from somatotroph-specific AIP knockout mice undergo hyperplastic
expansion and adenomatous change. (a) Representative photomicrograph of histologic
sections from control (left) and sAIPKO mouse pituitary glands at 18 weeks (middle) and 40
weeks of age (right). The upper panel is a hematoxylin and eosin stain illustrating the
adenomatous change of sAIPKO pituitary acidophils. The lower panel shows silver stained
histologic sections from control and sAIPKO mouse pituitary glands. There is a normal
cellular appearance in the control pituitary (left), hyperplastic appearance in the sAIPKO
pituitary at 18 weeks (middle), and adenomatous change in the sAIPKO pituitary at 40
weeks (right). Representative results are from triplicate samples in at least two independent
experiments. Scale bar represents 200; original magnification: 3200. (b) and (c) The numbers
of pituitary cells per acini are similar in control vs sAIPKO mice, but begin to increase in the
sAIPKO pituitaries after 12 weeks, such that by 18 weeks of age, twice as many cells appear
in the sAIPKO glands. Similarly, the mean acinar area of the adenohypophyses of control
mice remains constant throughout the lifespan, whereas the mean acinar area of the sAIPKO
adenohypophyses enlarges, becoming significantly larger (twofold) by 18 weeks, and
stabilizing at its maximal area at 40 weeks (*P , 0.01). Open bars, control; black, sAIPKO.
The number of age and sex-matched number of mice for each genotype is eight at age above
18 weeks old and four at age below 12 weeks old.
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pituitary sections from controlmice at 40weeks of age, on sections frompretumorigenic tissue at
18 weeks of age and on sections frommacroscopically visible pituitary adenomas at 40 weeks of
age in sAIPKO mice (Fig. 4). Immunohistochemistry of pituitary sections from control mice at
40 weeks of age revealed moderate p27 immunoreactivity. In pituitary sections from sAIPKO
mice at 18 weeks of age, p27 immunoreactivity appeared abundant, but was diminished in
adenomatous tissue (40 weeks of age). Immunohistochemistry of adenohypophysial tissue for
CDK4 revealed a diffuse patternwithmoderate level of expression in sections from controlmice,
and diffusely upregulated expression in sAIPKO mice at 18 weeks of age. In sections from
adenomatous pituitary tissue fromsAIPKOmice, the expression ofCDK4was roughly similar in
intensity to sAIPKO pretumorigenic pituitary sections, but accumulated in the perinuclear
region, as typical of cells traversing the G1-S transition (Fig. 5). In adenomas taken from
40-week-old sAIPKO mice, p27 expression was markedly reduced in both the nuclear and
cytosolic compartments. Thus, the overall expression of p27 is greater in the pretumorigenic
sAIPKO somatotrophs as compared with the controls somatotrophs, but the substantial ac-
cumulation of this CDKI in the cytoplasm suggests the possibility that cytoplasmic seques-
tration could impair its ability to induce growth arrest. Following adenomatous transformation,
p27 expression is globally reduced. This altered pattern of cell-cycle regulator expression
provides corroborative evidence that a loss of AIP function is characterized in early stages by
deregulated growth that consequently becomes permissive for adenomatous transformation.
Regarding the expression of estrogen receptors (ERs), ER-a expressionwasmore abundant
in both the pretumorigenic and adenomatous pituitary tissue from the sAIPKO mice as
compared with controls, as previously shown in the conventional AIP knockout mouse [14].
ER-b expression in the pituitary was minimal in both genotypes (Fig. 5 and data not shown).
E. sAIPKO Mice Present Diminished Response in Octreotide Acetate Suppression Test
In real-time RT-PCR for mouse somatistatin receptors (SSTRs) 1 to 5, both control and
sAIPKO mice presented the low expression of SSTR4. The expression of SSTR5 diminished
significantly with the tumorous changes of pituitary gland in sAIPKO mice [Fig. 6(a)].
In octreotide acetate suppression test, glucose level decreased significantly at both doses of
30 mg/kg and 500 mg/kg [Fig. 6(b)]. At suppression test with 30 mg/kg octreotide acetate,
control and sAIPKO mice with pituitary hyperplasia showed substantial decrease in GH
level, which were recovered at 120 minutes after injection [Fig. 6(c)]. With 500 mg/kg of
octreotide acetate, GH level was significantly suppressed to a similar level in both control
mice and sAIPKO mice with pituitary adenoma, which was persisted for 2 hours [Fig. 6(d)].
3. Discussion
In humans, germline mutations in the AIP gene confer an increased risk for the development
of pituitary adenomas, though the phenotypes of familial isolated pituitary adenoma andPAP
display incomplete penetrance [21]. It is unknown whether incomplete penetrance is a result
of somatic maintenance of the wild-type AIP allele in unaffected carriers, or whether an
insufficient number of transforming genetic events have yet to occur in the somatic tissue of
these individuals. Conventional heterozygousAip knockout mice have been shown to develop
pituitary adenomas with almost complete penetrance in later adulthood, a finding that has
validated AIP as a pituitary tumor suppressor gene in this predisposition syndrome [14].
Heterozygous Aip mice also exhibit a mildly altered secretory pattern of GH even before the
development of pituitary adenoma [22]. Furthermore, microarray analysis of mouse em-
bryonic fibroblasts revealed that dysfunctional Gai signaling increases cyclic adenosine
monophosphate synthesis leading to GH-secreting pituitary adenoma in conventional Aip
knockout mice [23]. In that study, Gai-2 protein, phosphorylated extracellular signal-
regulated kinases 1 and 2, and cyclic adenosine monophosphate response element-binding
protein expression levels were decreased both in human andmouseGH-secretingAIPmutant
pituitary adenomas. However, because the functional studies were performed in cell lines and
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mouse embryonic fibroblasts, it remains unproven whether downregulation of this pathway
plays a primary tumor initiating role in transformation of somatotrophs. Furthermore, due to
the embryonic lethal nature of biallelicAip deficiency, themolecular process of tumorigenesis
in pituitary itself is difficult to study in heterozygous Aip+/2 mice as a result of the random
timing with which the wild-type allele is inactivated [13].
Using sAIPKO mice, we examined the precise sequence of cellular and molecular alter-
ations that occur in the process of pituitary tumorigenesis associated with AIP deficiency. An
analysis of the temporal sequence of pathological events identified pituitary hyperplasia as a
precursor lesion for the development of pituitary adenoma. Our conditional, sAIPKO mice
develop pituitary adenomas earlier than conventional heterozygous Aip knockout mice
supporting the premise that functional inactivation of both Aip alleles is necessary for tu-
morigenesis. However, although somatotroph tumors in our sAIPKO mice develop earlier
than those in conventional Aip+/2 mice, they did not arise until middle adulthood, after a
period of proliferative growth. The relatively indolent course of neoplastic transformation of
pituitary somatotrophs suggests that loss of function of AIP alone is not sufficient for tu-
morigenesis. As applicable for virtually all forms of cancer, additional somatic mutations in
Figure 5. Immunohistochemistry analysis of control and somatotroph-specific AIP knockout
pituitary tissue indicates upregulation of ER-a and altered localization of selected cell cycle
regulators. Sections from paraffin embedded sAIPKO pituitaries show increased
immunoreactivity of the cyclin dependent kinase inhibitor p27 at 18 weeks, corresponding
temporally to the stage of hyperplasia as demonstrated by reticulin staining, as depicted in
Fig. 3(A). p27 immunoreactivity markedly diminishes in the adenomatous gland at 40 weeks.
CDK4 immunoreactivity is largely cytoplasmic in the control pituitary, but displays enhanced
perinuclear immunoreactivity in sAIPKO pituitaries at 18 weeks, which appears more
distinct in the adenomatous gland at 40 weeks. ER-a immunoreactivity is also increased in
sAIPKO pituitaries at both the hyperplastic and adenomatous stages. Representative results
are from triplicate samples in at least two independent experiments. Scale bar represents
500 mm; original magnification: 3400.
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genes that provide a selective advantage and/or generate genomic instability are probably
essential for tumor formation in this predisposition syndrome [24]. Given the delayed nature
with which the tumors emerge even with both Aip alleles inactivated from birth in mice, it is
our speculation that in humans with germline heterozygous AIP mutations, tumors arise
after loss of the somatic wild-type allele, due to accumulation of nucleotide substitutions,
small deletions or insertions, or epigenetic processes that result in gene silencing or
activation.
In accordance with the predilection for pituitary tumorigenesis, the biallelic loss of this
tumor suppressor in sAIPKO mice causes a postnatal stimulation of somatotroph pro-
liferation, manifesting pathologically as hyperplasia, and physiologically as GH and IGF-1
excess. Among the cell-cycle proteins that regulate the G1-S transition, CDK4, p27, and Rb
are particularly critical components in neuroendocrine tissues. The pituitary gland is par-
ticularly sensitive to genetic alteration of genes involved in the CDK4, p27, and Rb pathway
Figure 6. Somatotroph specific AIP knockout mice exhibit diminished responsiveness in
octreotide acetate suppression test. (a) mRNA expression of somatostatin receptor subtypes in
three conditions of control, hyperplasia, and tumor. Relative expression values were
measured compared with somatostatin receptor subtype 1 of control mice. (b) Changes of
glucose level after octreotide acetate injection at a dose of 30 mg/kg. (c, d) Changes of serum
GH level during octreotide suppression test at doses of 30 mg/kg and 500 mg/kg, respectively.
**P , 0.05 compared with the values before octreotide acetate injection in each control,
sAIPKO mice with hyperplastic pituitary gland, and sAIPKO mice with adenomatous
pituitary gland, respectively. Open bars and open circle, control; gray bars and black
rectangles, sAIPKO mice with hyperplasia; black bars and black circle, sAIPKO mice with
tumor. Number of mice in each group is five.
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[25]. CDK4 is uniquely essential for the postnatal proliferation of the anterior pituitary [26],
whereas knock-in or transgenicmice expressing a constitutively active CDK4 allele (resistant
to p16 inhibition) display the reciprocal phenotype of anterior lobe pituitary tumors [27, 28].
Moreover, transgenic overexpression of GH releasing hormone normally causes hyperplasia
and adenoma formation in the somatotroph, whereas it is ineffective in the Cdk42/2 genetic
background. In contrast, mice deficient for the cyclin dependent kinase p27kip1 (encoded by
Cdkn1b) exhibit pituitary adenomas and anterior pituitary lobe hyperplasia with nearly
complete penetrance by 10 months [29, 30]. Thus, in the face of abundant genetic evidence
indicating that the normal proliferation of the anterior pituitary requires normal CDK4 and
p27 activity, we chose to analyze their expression in the somatotrophs of the conditional Aip
knockout. On a molecular level, the pretumorigenic AIP deficient somatotrophs exhibit al-
terations in cell-cycle regulator expression consistent with one of a hyperproliferative state.
These changes include the redistribution of p27 from the nucleus to cytosol, perinuclear
accentuation of CDK4 localization, and general increase in ER-a expression, the latter of
which was also described in conventional Aip knockout mice pituitary tumors [14]. An
upregulation of CDK4 expression coinciding with transformation from the pretumorigenic to
the adenomatous state is consistent conceptually with prior evidence that this kinase plays a
proproliferative role in pituitary cell growth [28, 31]. Perinuclear CDK4 accumulation on the
cytosolic surfaces of the nuclear pores is a hallmark of the G1-S transition inmammalian cells
[32], and this particular pattern of CKD4 expression has been identified in the progression of
colonic neoplasia from normal epithelia to adenomas or carcinomas [33]. The CDKI p27,
encoded by CDKN1B, is a well-documented pituitary tumor suppressor, as it is underex-
pressed or absent in most human pituitary tumors [34], germline mutations in CDKN1B
cause a multiple endocrine neoplasia type 4 condition heralded by pituitary adenomas [20],
andCdkn1b disruption causes highly penetrant pituitary neoplasms inmice [29]. An unusual
finding in our studywas the apparent upregulation and redistribution of p27 from the nucleus
to cytosol in the pretumorigenic sAIPKO pituitaries. Despite its widely accepted tumor
suppressive role, some nonpituitary tumors exhibit prominent p27 expression; in such cases,
the protein is often mislocalized to the cytoplasm [35–37]. Because the growth-restraining
activity of p27 depends on its nuclear localization, the aberrant cytosolic accumulation of p27
in pretumorigenic sAIPKO pituitaries may be permissive for the proliferative response ob-
served [38]. By the time the adenomatous state evolves in the sAIPKOmice, p27 expression is
diminished altogether. Whether AIP directly participates in p27 cytoplasmic redistribution
as part of a molecular chaperone complex, or these changes result alterations in other sig-
naling pathways that converge upon p27 phosphorylation is not known, but it is relevant to
note that AIP plays a role as an adaptor protein in shuttling the AhR and other proteins to the
nucleus. Thus, taken together, the cell-cycle protein changes in the pretumorigenic state
portray a replicative signature, whereas those observed in the adenomatous state are re-
flective of neoplasia.
The AIP gene encodes the AhR–interacting protein, which is a cochaperone for the AhR in a
complex containing heat-shock proteins [39]. Aip has a broad range of interacting partners,
which participate in a diverse array of signaling pathways [39]. Which of these pathways
participates in somatotroph tumorigenesis as a result of AIP mutation has not been eluci-
dated. In in vitro studies of nonendocrine cells, AIP either prevents AhR-mediated tran-
scription or promotes its signaling, depending upon species and cell type [40]. AhR also
alternatively inhibits or stimulates or inhibits cell proliferation in a tissue and context de-
pendentmanner. The latter inhibitory effects have been shown to occur in association with an
increase in p27 levels [41].Moreover, like AIP, CDK4 exists in chaperone complexes with heat
shock protein 90 [42]. On the other hand, it is possible that the tumor suppressor properties of
AIP occur entirely independent of AhR actions [43]. Regardless of the significance of the
relationship between Aip and AhR, the results shown in this study of higher CDK4 and lower
p27 expression in the somatotroph Aip conditional knockout are conceptually consistent with
the loss of Aip tumor suppression advancing cell-cycle progression through enhanced Cdk4
function and diminished p27 activity, followed by cell proliferation and as yet undefined
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processes that promote adenomatous transformation. Whether this sequence of molecular
events occurs via AhR, or through one of many other interacting proteins in pituitary
somatotrophs, remains to be determined.
ER-a plays a pivotal role in the development of the pituitary gland, especially in trans-
differentiation of mammosomatotroph [2]. Because AhR, for which AIP acts as a cochaperone,
has been shown to exhibit substantial cross-talk with ER-a, Aip disruption could influence
AhR signaling, ER-a function, or both [44]. Although ER-a transcripts have not been dem-
onstrated in one study of human somatotroph adenomas [45], the sAIPKO mice display
increased expression of ER-a both at the hyperplastic and adenomatous stages. This in-
creased expression in the adult sAIPKO somatotrophs might occur as a consequence of Aip
interference with normal AhR expression, localization, and/or function, any of which might
explain the apparent sex-related phenotypic differences (exaggerated growth in females)
observed in the sAIPKO mice.
In the clinical aspect of AIP on medical responsiveness, acromegalic patients with AIP
mutation showed the resistance to somatostatin analogs [46]. Furthermore, pretreatment of
somatostatin analogs increased the expression of AIP in both in vivo and in vitro conditions
[47]. Both studies suggest that AIP plays an important role in the action of somatostatin
analogs in both familial and sporadic GH secreting pituitary adenoma [48]. In the sAIPKO
model, they exhibited the similar expression pattern of SSTR subtypes. As shown in human
studies [49], SSTR4 mRNA expression levels were low in both control and sAIPKO model.
Furthermore, with progression of pituitary tumorigenesis from hyperplasia to adenoma, the
expression of SSTR5 mRNA decreased significantly. The changes in SSTR5 suggest that
there exist substantial pathologic changes even between pituitary hyperplasia and adeno-
matous transformation. In a relatively low-dose octreotide suppression test, sAIPKO mice
showed diminished response inGH suppression, whichwere overcome by high dose octreotide
treatment. This result suggest that initiation of high-dose medical treatment should be
considered in acromegalic patients with mutation or decreased expression of AIP, although
the side effects of high-dose somatostatin analogs might be matter. To our knowledge, most
animals with pituitary adenoma had failed in proving the responsiveness for conventional
medications. However, sAIPKO mice showed the potentiality as an animal model in de-
velopment for new therapeutics for pituitary adenoma [50].
Strikingly, the expansion of the somatotroph population and ensuing state of GHexcess is
not manifested until well into murine adulthood, showing a distinct onset at 18 weeks in the
sAIPKO mice. To our knowledge, detailed analyses of the timing of AIP expression levels
have not been reported in the adenohypophysis of mice; however, there is a clear differential
response of the pituitary somatotrophs in sAIPKO vs control mice with respect to GH
secretion at a stage beyond that of the murine pubertal growth spurt, coinciding with
enhanced physical growth. Such findings are consistent with the concept that pituitary
somatotrophs exhibit an adaptive ability to respond to trophic stimuli with changes in cellmass
and hormone secretion, and that there are unique mechanisms regulating their inherent
plasticity in a precise, lineage-specific manner [51]. Notably, the phenotypic characterization
of a conditional knockout ofAip in the liver didnot report an increase inhepatocyte proliferation
or neoplasia, providing additional supporting evidence of the tissue-specific role of AIP in
regulating pituitary cell growth [52]. However, there was a limitation on analysis of serumGH
level. Pulsatile secretory pattern and longitudinal changes of serum GH in an identical mouse
was not evaluated in this study. Because GH is secreted in ultradian manner with secretory
bursts with 3-hour intervals [53], further evaluation on the rhythm of GH secretion could
suggest the important information about the role of AIP.
Finally, on a clinical level, the sAIPKOmice exhibit aggressive tumors that are relatively
resistant to the suppressive effects of octreotide, in parallel with observations of tumor
invasion and poor somatostatin analog responsiveness in humans with acromegaly who
harbor AIPmutations [46]. One study has shown that pretreatment of somatostatin analogs
increases the expression of AIP in both in vivo and in vitro conditions [47]. These findings
suggest that AIP is involved in somatostatin receptor signaling, and mediates the
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antisecretory or antiproliferative effects of somatostatin analogs in GH-secreting pituitary
adenomas [48]. SSTR2 has a 10-fold higher affinity for octreotide than SSTR5. Furthermore,
SSTR5 can form homo- or heterodimers with other G-protein–coupled receptors including
SSTRs and dopamine receptors, which modify the response to its ligand [54, 55]. Conse-
quently, altered SSTR subtype expression also influences medical responsiveness to so-
matostatin analogs. The SSTR subtype expression data presented here in the sAIPKO
model are mostly similar to controls, as has been shown in studies of human somatotroph
tumors that are resistant to therapy [56]. However, in the sAIPKOmodel, with progression
of pituitary tumorigenesis from hyperplasia to adenoma, the expression of SSTR5 mRNA
decreases significantly. Taboada et al. [49] reported that an increase in SSTR2 mRNA
expression and decrease SSTR2/SSTR5 mRNA ratio positively correlated with drug re-
sponsiveness of acromegalic patients. The sAIPKO mice display a similar SSTR2 mRNA and
decreased SSTR5mRNA expression, as the control, illustrating that the effect of shifted ratio of
SSTR2/SSTR5 could be different from that of human acromegalic patients. In a relatively low-
dose octreotide suppression test, sAIPKOmice showed diminished response inGH suppression,
which was overcome by high-dose octreotide treatment. This result suggests that rapid esca-
lation of somatostatin therapy might be considered in acromegalic patients with known AIP
mutations who are likely to exhibit somatostatin analog resistance [46].
There were several limitations in this study. First, the proliferation index of pituitary
adenoma such as Ki67 was not evaluated in this study. Because histopathologic changes could
only occur at a single time point, it was not able to be statedwith certainty that foci of increased
proliferation existed prior to transformation to adenoma. However, the consistent findings of
hyperplasia in the mutant pituitaries at the 18-week mark, with adenomas found at later time
points, supports theoretically for hyperplasia preceding adenomatous transformation. Second,
there was not enough number of mice in the octreotide suppression test. Although there were
consistent changes of GH level in each animal group, further studies evaluating the effect of
octreotide on sAIPKO mice should be necessary with more number of mice.
In conclusion, in view of our findings using the conditional sAIPKOmodel, we propose that
AIP deficiency as it occurs in the human condition of familial isolated pituitary adenoma
predisposes to pituitary neoplasia through the following series of events: (1) genetic loss of the
wild-type allele; (2) sustained cellular proliferation, characterized by an insensitivity to
inhibitory hormonal feedback; and (3) a consequential greater rate of cell cycling leading to
the acquisition of somatic mutations or other genetic events that drive neoplastic trans-
formation. The conditional sAIPKO model has furthermore uncovered a novel potential
physiological role in the negative regulation of somatotroph proliferation andGH release that
may have implications for the understanding and treatment of adult-onset GH deficiency in
humans.
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